Dr. Tijana Fazlagic is the Executive Director of Therapeutic Assessment & Access, part of the Pharmaceutical, Laboratory & Blood Services Division at the British Columbia Ministry of Health. Dr. Fazlagic’s responsibilities include leadership of the formulary management, specialty medicines, precision medicine and genetic services and the business team. Dr. Fazlagic represents BC on various committees including the Canadian Agency for Drugs and Technologies in Health and pan-Canadian Pharmaceutical Alliance. Dr. Fazlagic holds a Doctor of Pharmacy degree from the University of Florida, a Master of Science and a Bachelor of Science degrees in Pharmacy from the University of Saskatchewan.
Day 1 Oct 28, 2025
2:30 pm
PANEL
Gain Best Practice in Negotiating Pricing
With individual provinces employing various strategies to manage drug costs effectively, develop your best practice in negotiating sustainable pricing whilst ensuring patients have the access they need. Take back to your office strategies to:
- Understand Tiered Pricing Frameworks (TPFs) and how the pCPA evaluates and establishes prices for innovative and generic products entering or exiting the Canadian market.
- Identify when generic substitution of brand-name drugs and other methods to reduce expenditure is appropriate.
- Examine differences across the provinces, where they align, and how they incorporate this when building their pricing models for different drugs.
Optimize collaborative and province-specific tactics to balance cost containment with equitable access to essential medications.
Day 2 Oct 29, 2025
